Mandate

VINGE ADVISES GRÄNGES IN CONNECTION WITH THE LISTING ON NASDAQ STOCKHOLM

October 10, 2014

Vinge advises Gränges AB (publ) in connection with the company’s listing on Nasdaq Stockholm.

Gränges is a leading global supplier of rolled products for the brazed aluminum heat exchanger industry. The Company develops, produces and markets advanced materials that enhance both production economy during the customer manufacturing process, as well as the performance of the final products, the brazed heat exchangers. Gränges’ vision is to help create smaller, lighter and more designable heat exchangers, to increase economic efficiency and reduce environmental impact. The Swedish language prospectus was published on 29 September 2014 and the first day of trading was 10 October 2014. The offering price has been set at SEK 42.50 per share, corresponding to a market value of Gränges of approximately SEK 3,200 million.

Vinge’s team primarily consisted of Carl Gustaf de Geer, Jesper Schönbeck, Charlotte Levin, Katarina Nilsson, Kristian Ford, Rikard Lindahl, Filip Brosset and Henrik Jonsson.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026